Compare Ascendis Pharma A/S (ASND) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs National Beverage Corp. — how do they compare? Ascendis Pharma A/S trades at $265.33 (market cap $17.74B), while National Beverage Corp. trades at $30.96 (market cap $3.17B). The key difference: Ascendis Pharma A/S is far larger — about 5.6× National Beverage Corp.'s market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| ASND | FIZZ | |
|---|---|---|
Market Cap | $17.74B | $3.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $47.69 |
52-Week Low | $163.32 | $31.00 |
Enterprise Value | $18.11B | $2.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
National Beverage Corp (FIZZ) trades at $33.82, up 3.93% today, showing mixed signals with bearish technical indicators but strong profitability metrics including 15.56% net margin and 34.03% ROE. Recent Q2 2026 earnings missed expectations, but the company declared a $3.25 special dividend payable July 30, 2026. Cash flow trends show volatility, with 2025 net cash flow negative $133 million due to significant financing outflows.
The outlook remains cautious with analyst consensus leaning bearish (50% sell ratings) despite solid fundamentals. Key risks include competitive pressures and consumer weakness, while the special dividend provides near-term shareholder value. Investors should weigh strong profitability against recent earnings misses and negative cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
